Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linagliptin and Pioglitazone Initial Combination Therapy in Type 2 Diabetes
NCT01183013Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2010
- Primary completion
- Feb 2013
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of linagliptin in type 2 diabetes mellitus (T2DM), sponsored by Boehringer Ingelheim. Started Aug 2010; status: completed.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01183013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01183013.